{
    "nctId": "NCT01160094",
    "briefTitle": "Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)",
    "officialTitle": "Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)",
    "overallStatus": "COMPLETED",
    "conditions": "Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 288,
    "primaryOutcomeMeasure": "Time to disease progression",
    "eligibilityCriteria": "* Women with ErbB2+ MBC (ErbB2 expression confirmed by immunohistochemistry or FISH/CISH, either in the primary tumor or in the metastasis, according to the institution's common practice);\n* Older than 18 years old;\n* Have received prior treatment with trastuzumab-containing regimen for ErbB2+ breast cancer;\n* Progressing after trastuzumab-containing regimen either used for the treatment of metastatic disease or progressing after adjuvant /neoadjuvant trastuzumab treatment;\n* Eligible to start standard treatment with Lapatinib-capecitabine at conventional doses, OR receiving standard treatment with\n* Lapatinib-capecitabine at conventional doses, for no longer than 10 weeks from the start of the treatment to the date of inclusion in the study;\n* Signed consent to participate and release information for this study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}